Cargando…

Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma

There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised that multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological parameters and pharmacokinetic models might detect early biological responses to immunotherapy for g...

Descripción completa

Detalles Bibliográficos
Autores principales: Rygh, Cecilie Brekke, Wang, Jian, Thuen, Marte, Gras Navarro, Andrea, Huuse, Else Marie, Thorsen, Frits, Poli, Aurelie, Zimmer, Jacques, Haraldseth, Olav, Lie, Stein Atle, Enger, Per Øyvind, Chekenya, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182474/
https://www.ncbi.nlm.nih.gov/pubmed/25268630
http://dx.doi.org/10.1371/journal.pone.0108414
_version_ 1782337535419088896
author Rygh, Cecilie Brekke
Wang, Jian
Thuen, Marte
Gras Navarro, Andrea
Huuse, Else Marie
Thorsen, Frits
Poli, Aurelie
Zimmer, Jacques
Haraldseth, Olav
Lie, Stein Atle
Enger, Per Øyvind
Chekenya, Martha
author_facet Rygh, Cecilie Brekke
Wang, Jian
Thuen, Marte
Gras Navarro, Andrea
Huuse, Else Marie
Thorsen, Frits
Poli, Aurelie
Zimmer, Jacques
Haraldseth, Olav
Lie, Stein Atle
Enger, Per Øyvind
Chekenya, Martha
author_sort Rygh, Cecilie Brekke
collection PubMed
description There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised that multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological parameters and pharmacokinetic models might detect early biological responses to immunotherapy for glioblastoma targeting NG2/CSPG4 with mAb9.2.27 combined with natural killer (NK) cells. Contrast enhanced conventional T1-weighted MRI at 7±1 and 17±2 days post-treatment failed to detect differences in tumour size between the treatment groups, whereas, follow-up scans at 3 months demonstrated diminished signal intensity and tumour volume in the surviving NK+mAb9.2.27 treated animals. Notably, interstitial volume fraction (v(e)), was significantly increased in the NK+mAb9.2.27 combination therapy group compared mAb9.2.27 and NK cell monotherapy groups (p = 0.002 and p = 0.017 respectively) in cohort 1 animals treated with 1 million NK cells. v(e) was reproducibly increased in the combination NK+mAb9.2.27 compared to NK cell monotherapy in cohort 2 treated with increased dose of 2 million NK cells (p<0.0001), indicating greater cell death induced by NK+mAb9.2.27 treatment. The interstitial volume fraction in the NK monotherapy group was significantly reduced compared to mAb9.2.27 monotherapy (p<0.0001) and untreated controls (p = 0.014) in the cohort 2 animals. NK cells in monotherapy were unable to kill the U87MG cells that highly expressed class I human leucocyte antigens, and diminished stress ligands for activating receptors. A significant association between apparent diffusion coefficient (ADC) of water and v(e) in combination NK+mAb9.2.27 and NK monotherapy treated tumours was evident, where increased ADC corresponded to reduced v(e) in both cases. Collectively, these data support histological measures at end-stage demonstrating diminished tumour cell proliferation and pronounced apoptosis in the NK+mAb9.2.27 treated tumours compared to the other groups. In conclusion, v(e) was the most reliable radiological parameter for detecting response to intralesional NK cellular therapy.
format Online
Article
Text
id pubmed-4182474
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41824742014-10-07 Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma Rygh, Cecilie Brekke Wang, Jian Thuen, Marte Gras Navarro, Andrea Huuse, Else Marie Thorsen, Frits Poli, Aurelie Zimmer, Jacques Haraldseth, Olav Lie, Stein Atle Enger, Per Øyvind Chekenya, Martha PLoS One Research Article There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised that multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological parameters and pharmacokinetic models might detect early biological responses to immunotherapy for glioblastoma targeting NG2/CSPG4 with mAb9.2.27 combined with natural killer (NK) cells. Contrast enhanced conventional T1-weighted MRI at 7±1 and 17±2 days post-treatment failed to detect differences in tumour size between the treatment groups, whereas, follow-up scans at 3 months demonstrated diminished signal intensity and tumour volume in the surviving NK+mAb9.2.27 treated animals. Notably, interstitial volume fraction (v(e)), was significantly increased in the NK+mAb9.2.27 combination therapy group compared mAb9.2.27 and NK cell monotherapy groups (p = 0.002 and p = 0.017 respectively) in cohort 1 animals treated with 1 million NK cells. v(e) was reproducibly increased in the combination NK+mAb9.2.27 compared to NK cell monotherapy in cohort 2 treated with increased dose of 2 million NK cells (p<0.0001), indicating greater cell death induced by NK+mAb9.2.27 treatment. The interstitial volume fraction in the NK monotherapy group was significantly reduced compared to mAb9.2.27 monotherapy (p<0.0001) and untreated controls (p = 0.014) in the cohort 2 animals. NK cells in monotherapy were unable to kill the U87MG cells that highly expressed class I human leucocyte antigens, and diminished stress ligands for activating receptors. A significant association between apparent diffusion coefficient (ADC) of water and v(e) in combination NK+mAb9.2.27 and NK monotherapy treated tumours was evident, where increased ADC corresponded to reduced v(e) in both cases. Collectively, these data support histological measures at end-stage demonstrating diminished tumour cell proliferation and pronounced apoptosis in the NK+mAb9.2.27 treated tumours compared to the other groups. In conclusion, v(e) was the most reliable radiological parameter for detecting response to intralesional NK cellular therapy. Public Library of Science 2014-09-30 /pmc/articles/PMC4182474/ /pubmed/25268630 http://dx.doi.org/10.1371/journal.pone.0108414 Text en © 2014 Rygh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Rygh, Cecilie Brekke
Wang, Jian
Thuen, Marte
Gras Navarro, Andrea
Huuse, Else Marie
Thorsen, Frits
Poli, Aurelie
Zimmer, Jacques
Haraldseth, Olav
Lie, Stein Atle
Enger, Per Øyvind
Chekenya, Martha
Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma
title Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma
title_full Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma
title_fullStr Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma
title_full_unstemmed Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma
title_short Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma
title_sort dynamic contrast enhanced mri detects early response to adoptive nk cellular immunotherapy targeting the ng2 proteoglycan in a rat model of glioblastoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182474/
https://www.ncbi.nlm.nih.gov/pubmed/25268630
http://dx.doi.org/10.1371/journal.pone.0108414
work_keys_str_mv AT ryghceciliebrekke dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT wangjian dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT thuenmarte dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT grasnavarroandrea dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT huuseelsemarie dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT thorsenfrits dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT poliaurelie dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT zimmerjacques dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT haraldsetholav dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT liesteinatle dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT engerperøyvind dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma
AT chekenyamartha dynamiccontrastenhancedmridetectsearlyresponsetoadoptivenkcellularimmunotherapytargetingtheng2proteoglycaninaratmodelofglioblastoma